Anlon Healthcare Reports Massive Growth in Q1FY27; Achieves 163% Topline Jump Amid Strategic Acquisitions

Anlon Healthcare Reports Massive Growth in Q1FY27; Achieves 163% Topline Jump Amid Strategic Acquisitions​

Anlon Healthcare Limited, a leading manufacturer of high-purity pharmaceutical intermediates and Active Pharmaceutical Ingredients (APIs) in India, has announced its unaudited consolidated financial results for the first quarter of fiscal year 2027 (Q1FY27). The company reported significant growth across all key metrics, driven by diversification into Finished Dosage Formulations (FDF).

The results reflect a robust performance as Anlon strengthens its integrated pharmaceutical platform.

Consolidated Financial Performance Highlights​

Anlon Healthcare demonstrated exceptional financial strength during the quarter. The consolidated figures show substantial year-on-year increases in total income, EBITDA, and Profit After Tax (PAT).

Strategic Expansion and Operational Developments​

The company expanded its scope during the quarter by acquiring a 63.98% stake in Remember India Health Links Pvt. Ltd. for ₹5.38 Crore, completing the transaction on May 8, 2026. This acquisition made Anlon Healthcare the parent entity of the unit and marked a strategic entry into the Finished Dosage Formulations (FDF) segment.

Key developments defining Anlon’s move toward becoming an integrated pharmaceutical company include:

• Broadening its product portfolio by gaining access to over 30 formulation dossiers, bolstering capabilities in tablets, capsules, and various other pharmaceutical formulations.
• Expanding market presence into B2B APIs, domestic retail markets, and hospital sectors, thereby creating a wider healthcare platform.
• Achieving operational synergies through the integration of manufacturing processes with quality control processes, enhancing long-term scalability and efficiency.

Management Commentary on Results​

Punitkumar Rasadia, Chairman and Managing Director of Anlon Healthcare Limited, commented on the strong performance, noting that the results reflect the resilience of the business model and continued customer confidence.

"We commenced FY27 on a very strong note," Mr. Rasadia stated. "The 163.02% growth in consolidated Total Income to ₹87.62 Crore, coupled with 150.14% growth in EBITDA to ₹15.65 Crore and 133.13% growth in Profit After Tax to ₹8.28 Crore, demonstrates the strength of our diversified pharmaceutical portfolio."

He highlighted that the acquisition of Remember India Health Links Pvt. Ltd. was a crucial milestone for entering the FDF segment. This move allows the company to expand its presence across B2B APIs, domestic retail, and hospital markets, significantly enhancing manufacturing capabilities alongside strategic investments in Apiqo Organics and Bizotic Lifescience.

Looking ahead, management remains committed to expanding presence in regulated markets and scaling the CDMO business. The company stated confidence in achieving a long-term revenue CAGR of approximately 30% over the next three years, while maintaining EBITDA margins between 25% and 30%.

Company Profile​

Incorporated in 2013 and headquartered in Rajkot, Gujarat, Anlon Healthcare Limited is a research-driven pharmaceutical company. The company specializes in manufacturing high-purity pharmaceutical intermediates and APIs. It operates across over 15 countries, serving the pharmaceutical, nutraceutical, personal care, and animal health industries.

Anlon is noted as one of the few manufacturers of key APIs such as Loxoprofen Sodium Dihydrate, Ketoprofen, and Dexketoprofen Trometamol. With an installed capacity ranging from 1,400 to 1,600 MTPA and four dedicated R&D centers, Anlon continues to advance health through innovation and quality.

AHCL Stock Price Movement​

Shares of Anlon Healthcare Limited are edging higher to ₹14.54 as of 11:16 AM today, having climbed 0.14% in live trading. The stock sees sustained interest, with over 3.35 million shares transacted so far in the market session.